188 related articles for article (PubMed ID: 15538041)
1. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations.
Kusama M; Kaise H; Nakayama S; Ota D; Misaka T; Aoki T
Breast Cancer Res Treat; 2004 Nov; 88(1):9-16. PubMed ID: 15538041
[TBL] [Abstract][Full Text] [Related]
2. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
[TBL] [Abstract][Full Text] [Related]
3. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
Tominaga T; Kimijima I; Kimura M; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
Jpn J Clin Oncol; 2010 Jul; 40(7):627-33. PubMed ID: 20382637
[TBL] [Abstract][Full Text] [Related]
4. Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study.
Anan K; Mitsuyama S; Yanagita Y; Kimura M; Doihara H; Komaki K; Kusama M; Ikeda T
Breast Cancer Res Treat; 2011 Aug; 128(3):775-81. PubMed ID: 21638048
[TBL] [Abstract][Full Text] [Related]
5. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
Yamamoto Y; Kawazoe T; Iwase H
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
Pyrhönen S; Ellmén J; Vuorinen J; Gershanovich M; Tominaga T; Kaufmann M; Hayes DF
Breast Cancer Res Treat; 1999 Jul; 56(2):133-43. PubMed ID: 10573106
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
Masuoka H; Mori M; Nomura N; Sakurai M; Yoshida K; Usuda N; Shirai H; Shimokawara I; Asaishi K
Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
[TBL] [Abstract][Full Text] [Related]
8. [Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].
Gershanovich ML; Garin AM; Baltinia D; Kurvet A; Kangas L; Ellmen Iu
Vopr Onkol; 1997; 43(6):587-95. PubMed ID: 9479357
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
10. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer.
Joensuu H; Holli K; Oksanen H; Valavaara R
Breast Cancer Res Treat; 2000 Oct; 63(3):225-34. PubMed ID: 11110056
[TBL] [Abstract][Full Text] [Related]
11. Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
Shien T; Doihara H; Sato N; Anan K; Komaki K; Miyauchi K; Yanagita Y; Fujisawa T; Mitsuyama S; Kanbayashi C; Kusama M; Kimura M; Jinno H; Sano M; Ikeda T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):269-275. PubMed ID: 29196963
[TBL] [Abstract][Full Text] [Related]
12. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
13. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
Jiang Z; Song S; Liu X
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
[TBL] [Abstract][Full Text] [Related]
15. Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins.
Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
Clin Biochem; 2007 Jun; 40(9-10):623-8. PubMed ID: 17425952
[TBL] [Abstract][Full Text] [Related]
16. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
Saarto T; Blomqvist C; Ehnholm C; Taskinen MR; Elomaa I
J Clin Oncol; 1996 Feb; 14(2):429-33. PubMed ID: 8636753
[TBL] [Abstract][Full Text] [Related]
17. Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer.
Song D; Hu Y; Diao B; Miao R; Zhang B; Cai Y; Zeng H; Zhang Y; Hu X
BMC Cancer; 2021 Jul; 21(1):798. PubMed ID: 34246237
[TBL] [Abstract][Full Text] [Related]
18. Toremifene for breast cancer: a review of 20 years of data.
Vogel CL; Johnston MA; Capers C; Braccia D
Clin Breast Cancer; 2014 Feb; 14(1):1-9. PubMed ID: 24439786
[TBL] [Abstract][Full Text] [Related]
19. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin.
Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
Cancer Chemother Pharmacol; 2008 May; 61(6):933-41. PubMed ID: 17668211
[TBL] [Abstract][Full Text] [Related]
20. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
